Analysts’ Recent Ratings Changes for CareDx (CDNA)

Several analysts have recently updated their ratings and price targets for CareDx (NASDAQ: CDNA):

• 7/16/2026 – CareDx had its “hold” rating reaffirmed by Craig Hallum. They now have a $35.00 price target on the stock.
• 7/16/2026 – CareDx was upgraded by William Blair to “hold”.
• 7/16/2026 – CareDx had its price target raised by BTIG Research from $28.00 to $45.00. They now have a “buy” rating on the stock.
• 7/15/2026 – CareDx was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
• 6/26/2026 – CareDx was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
• 5/27/2026 – CareDx had its “sell (d)” rating reaffirmed by Weiss Ratings.

Insider Transactions at CareDx

In other CareDx news, CEO John Walter Hanna, Jr. sold 39,900 shares of the business’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $29.24, for a total value of $1,166,676.00. Following the completion of the sale, the chief executive officer directly owned 661,959 shares of the company’s stock, valued at $19,355,681.16. The trade was a 5.68% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Hannah Valantine sold 12,103 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $23.11, for a total transaction of $279,700.33. Following the transaction, the director directly owned 36,686 shares in the company, valued at approximately $847,813.46. This trade represents a 24.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 78,936 shares of company stock valued at $2,093,708 in the last quarter. 2.40% of the stock is currently owned by company insiders.

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.